EE513 Assessing the Economic Impact of Biosimilars in the U.S.: A cost analysis of Infliximab, Trastuzumab, and Rituximab
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.2109
https://www.valueinhealthjournal.com/article/S1098-3015(25)02238-7/fulltext
Title :
EE513 Assessing the Economic Impact of Biosimilars in the U.S.: A cost analysis of Infliximab, Trastuzumab, and Rituximab
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02238-7&doi=10.1016/j.jval.2025.04.2109
First page :
Section Title :
Open access? :
No
Section Order :
10276